Novocure Announces Optune Now Available at more than 150 Leading Cancer Centers across the United States

Optune, a Tumor Treating Fields (TTFields) delivery system, provides a novel, non-invasive treatment for recurrent glioblastoma, the most common malignant primary brain cancer

Optune (Photo Credit: Business Wire)

NEW YORK--()--Novocure™ announced today that more than 150 treatment centers have been certified to prescribe Optune™ to patients with recurrent glioblastoma (GBM). GBM is the most common form of malignant primary brain cancer with approximately 10,000 patients diagnosed each year in the US. The disease is widely recognized as one of the deadliest forms of cancer and has very limited treatment options. TTFields delivered by Optune is the latest therapy approved by the Food and Drug Administration (FDA) for this hard to treat disease.

Optune is a novel, antimitotic therapy approved in the US for the treatment of adult patients with recurrent GBM. It is available by prescription from centers whose clinical staffs have been trained to use the system.

Recently trained treatment centers and their key contacts include:

  • Dana-Farber Cancer Institute; David Reardon, MD and Patrick Wen, MD
  • Duke Cancer Institute; Henry Friedman, MD
  • Mayo Clinic Cancer Center; Jan Buckner, MD
  • Roswell Park Cancer Institute; Robert Fenstermaker, MD
  • Stanford Cancer Institute; Seema Nagpal, MD
  • Texas Oncology; Morris Groves, MD
  • University of Texas MD Anderson Cancer Center; Paul Brown, MD

For a complete list of certified treatment centers, please visit http://www.optune.com/find-treament-center.

“Our goal as clinicians is to treat cancer patients with cutting edge therapies and I am pleased to see that Optune is now so widely available for those patients fighting recurrent GBM,” said David Reardon, MD, Clinical Director, Center for Neuro-Oncology, Dana-Farber Cancer Institute.

“We are pleased to offer Optune to GBM patients at our institution” says Dr. Henry Friedman, Deputy Director, The Preston Robert Tisch Brain Tumor Center at Duke. “We are also looking forward to potential opportunities to conduct future clinical research with Novocure”.

“We are honored to add such a prestigious group of new centers to our current list of certified providers,” said Pritesh Shah, US General Manager. “With the growing body of clinical evidence and as more physicians gain practical experience with Optune, we have the opportunity to establish TTFields therapy as a standard-of-care for recurrent GBM.”

About Tumor Treating Fields Therapy

Tumor Treating Fields (TTFields) therapy is delivered by a portable, non-invasive medical device designed for continuous use by patients. In vitro and in vivo studies have shown that TTFields therapy slows and reverses tumor growth by inhibiting mitosis, the process by which cells divide and replicate. TTFields therapy creates a low intensity, alternating electric field within a tumor that exerts physical forces on electrically charged cellular components, preventing the normal mitotic process and causing cancer cell death.

Approved Indication

The US FDA has approved the TTFields therapy delivery system, Optune (previously known as the NovoTTF-100A System), for use as a treatment for adult patients (22 years of age or older) with histologically-confirmed GBM, following histologically or radiologically-confirmed recurrence in the supra-tentorial region of the brain after receiving chemotherapy. The device is intended to be used as monotherapy, and is intended as an alternative to standard medical therapy for GBM after surgical and radiation options have been exhausted. Patients should only use Optune under the supervision of a physician properly trained in use of the device. Full prescribing information is available at www.optune.com/safety or by calling toll free 1-855-281-9301.

About Novocure

Novocure is a private Jersey Isle oncology company pioneering a novel therapy for solid tumors called TTFields. Novocure US operations are based in Portsmouth, NH and New York, NY. Additionally, the company has offices in Switzerland and Japan and a research center in Haifa, Israel. For additional information about the company, please visit www.novocure.com.

Contacts

Novocure
Media:
Peter Melnyk, 212-767-7534
pmelnyk@novocure.com
or
Investor:
Ashley Cordova, 212-767-7558
acordova@novocure.com

Release Summary

Novocure Announces Optune Now Available at more than 150 Leading Cancer Centers across the United States

Contacts

Novocure
Media:
Peter Melnyk, 212-767-7534
pmelnyk@novocure.com
or
Investor:
Ashley Cordova, 212-767-7558
acordova@novocure.com